# Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST

> **NCT05751733** · NA · RECRUITING · sponsor: **Xiangya Hospital of Central South University** · enrollment: 258 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumors

## Interventions

- **DRUG:** Apatinib Mesylate
- **DRUG:** Sunitinib, Imatinib dosage, Dasatinib, Reveratinib

## Key facts

- **NCT ID:** NCT05751733
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2027-01-01
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2023-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05751733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05751733, "Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05751733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*